Treatment is more successful the earlier cancer is detected. Unfortunately, today, cancer screening is full of challenges:
Patients and the medical community have been eager for a future where accuracy and efficiency and can be achieved in a single non-invasive test. By combining deep data science with a new approach in genomic sequencing, Quantgene is making this possibility a reality.
All tumors shed cell-free DNA (cfDNA) at the earliest stages of growth. These cfDNA fragments can be detected through liquid biopsy in a small blood sample. For some time, cell-free DNA in the blood has been recognized as a highly precise and accurate biomarker of cancer. However, to-date, no available technology has been able to fully unlock this approach for early detection.
Quantgene’s QUANTUM ARRAY is the first fully-integrated technology stack to combine lab chemistry with data and machine learning processes in one seamless system. This engine allows us to detect a single cfDNA molecule of multiple types of cancers from one blood draw.
The full-integration of the QUANTUM ARRAY tech stack also enables:
QUANTUM ARRAY unlocks full visibility of every data point from clinical reports all the way down to lab chemistry. The result is confidence in the accuracy of our results.
Rapid and continuous improvement
QUANTUM ARRAY is a system that continues to learn and improve with every sample to:
Detection and beyond: Quantgene is a comprehensive clinical framework informed by
In the event of a positive test result, our team of experts provides clinical recommendations to help bring clarity to the next steps in diagnosis.
Access for all: Cancer doesn't wait and neither should we. Our goal is to bring early cancer screening to everyone and protect the lives of all patients. We want to move fast, in partnership with regulatory bodies and organizations, to make our new technology the gold standard of care.